Clinical Trial Update: Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating rifapentine plus moxifloxacin for pulmonary tuberculosis was terminated. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Moxifloxacin (moxifloxacin)
• rifapentine (rifapentine)

Snippet

Sponsor: Johns Hopkins University | Conditions: Tuberculosis | Phase 2 | Status: TERMINATED | Results posted: 2017-04-20